![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LXN |
Gene summary for LXN |
![]() |
Gene information | Species | Human | Gene symbol | LXN | Gene ID | 56925 |
Gene name | latexin | |
Gene Alias | ECI | |
Cytomap | 3q25.32 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q9BS40 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56925 | LXN | LZE4T | Human | Esophagus | ESCC | 6.78e-09 | 1.20e-01 | 0.0811 |
56925 | LXN | LZE7T | Human | Esophagus | ESCC | 9.96e-06 | 1.02e-01 | 0.0667 |
56925 | LXN | P2T-E | Human | Esophagus | ESCC | 5.83e-28 | 6.82e-01 | 0.1177 |
56925 | LXN | P4T-E | Human | Esophagus | ESCC | 2.91e-30 | 8.25e-01 | 0.1323 |
56925 | LXN | P8T-E | Human | Esophagus | ESCC | 1.30e-30 | 6.25e-01 | 0.0889 |
56925 | LXN | P10T-E | Human | Esophagus | ESCC | 3.50e-12 | 5.28e-02 | 0.116 |
56925 | LXN | P11T-E | Human | Esophagus | ESCC | 2.53e-02 | -8.39e-03 | 0.1426 |
56925 | LXN | P16T-E | Human | Esophagus | ESCC | 6.16e-03 | -1.74e-01 | 0.1153 |
56925 | LXN | P22T-E | Human | Esophagus | ESCC | 9.68e-30 | 4.16e-01 | 0.1236 |
56925 | LXN | P23T-E | Human | Esophagus | ESCC | 3.16e-02 | -2.33e-02 | 0.108 |
56925 | LXN | P26T-E | Human | Esophagus | ESCC | 9.85e-18 | -1.84e-02 | 0.1276 |
56925 | LXN | P28T-E | Human | Esophagus | ESCC | 1.09e-09 | 1.32e-01 | 0.1149 |
56925 | LXN | P32T-E | Human | Esophagus | ESCC | 7.39e-13 | -2.01e-02 | 0.1666 |
56925 | LXN | P38T-E | Human | Esophagus | ESCC | 1.76e-06 | 7.51e-02 | 0.127 |
56925 | LXN | P42T-E | Human | Esophagus | ESCC | 6.73e-04 | -8.97e-02 | 0.1175 |
56925 | LXN | P44T-E | Human | Esophagus | ESCC | 4.37e-08 | 5.31e-01 | 0.1096 |
56925 | LXN | P47T-E | Human | Esophagus | ESCC | 1.27e-02 | 1.23e-01 | 0.1067 |
56925 | LXN | P48T-E | Human | Esophagus | ESCC | 8.36e-05 | 3.19e-01 | 0.0959 |
56925 | LXN | P49T-E | Human | Esophagus | ESCC | 2.45e-02 | 2.18e-01 | 0.1768 |
56925 | LXN | P52T-E | Human | Esophagus | ESCC | 3.19e-06 | 9.57e-03 | 0.1555 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00226044 | Colorectum | FAP | regulation of cell morphogenesis | 87/2622 | 309/18723 | 4.89e-11 | 1.87e-08 | 87 |
GO:00343293 | Colorectum | FAP | cell junction assembly | 105/2622 | 420/18723 | 1.03e-09 | 2.18e-07 | 105 |
GO:00064174 | Colorectum | FAP | regulation of translation | 111/2622 | 468/18723 | 8.47e-09 | 1.13e-06 | 111 |
GO:00430873 | Colorectum | FAP | regulation of GTPase activity | 85/2622 | 348/18723 | 1.20e-07 | 7.68e-06 | 85 |
GO:00615643 | Colorectum | FAP | axon development | 106/2622 | 467/18723 | 1.98e-07 | 1.21e-05 | 106 |
GO:00109753 | Colorectum | FAP | regulation of neuron projection development | 102/2622 | 445/18723 | 2.04e-07 | 1.24e-05 | 102 |
GO:00074093 | Colorectum | FAP | axonogenesis | 97/2622 | 418/18723 | 2.20e-07 | 1.30e-05 | 97 |
GO:00107203 | Colorectum | FAP | positive regulation of cell development | 72/2622 | 298/18723 | 1.67e-06 | 6.99e-05 | 72 |
GO:00313463 | Colorectum | FAP | positive regulation of cell projection organization | 82/2622 | 353/18723 | 1.78e-06 | 7.35e-05 | 82 |
GO:00083603 | Colorectum | FAP | regulation of cell shape | 43/2622 | 154/18723 | 4.55e-06 | 1.52e-04 | 43 |
GO:00507672 | Colorectum | FAP | regulation of neurogenesis | 82/2622 | 364/18723 | 6.28e-06 | 1.96e-04 | 82 |
GO:00507702 | Colorectum | FAP | regulation of axonogenesis | 42/2622 | 154/18723 | 1.11e-05 | 3.10e-04 | 42 |
GO:00435472 | Colorectum | FAP | positive regulation of GTPase activity | 61/2622 | 255/18723 | 1.39e-05 | 3.73e-04 | 61 |
GO:00508083 | Colorectum | FAP | synapse organization | 91/2622 | 426/18723 | 1.90e-05 | 4.74e-04 | 91 |
GO:00605622 | Colorectum | FAP | epithelial tube morphogenesis | 71/2622 | 325/18723 | 7.23e-05 | 1.33e-03 | 71 |
GO:00507691 | Colorectum | FAP | positive regulation of neurogenesis | 53/2622 | 225/18723 | 7.65e-05 | 1.37e-03 | 53 |
GO:00351482 | Colorectum | FAP | tube formation | 38/2622 | 148/18723 | 1.17e-04 | 1.91e-03 | 38 |
GO:00507721 | Colorectum | FAP | positive regulation of axonogenesis | 24/2622 | 79/18723 | 1.35e-04 | 2.16e-03 | 24 |
GO:00519601 | Colorectum | FAP | regulation of nervous system development | 89/2622 | 443/18723 | 2.32e-04 | 3.25e-03 | 89 |
GO:00018413 | Colorectum | FAP | neural tube formation | 28/2622 | 102/18723 | 2.71e-04 | 3.64e-03 | 28 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
SEMA3D | NRP1_PLXNA2 | SEMA3D_NRP1_PLXNA2 | SEMA3 | Breast | ADJ |
SEMA3D | NRP2_PLXNA2 | SEMA3D_NRP2_PLXNA2 | SEMA3 | Breast | ADJ |
SEMA6A | PLXNA2 | SEMA6A_PLXNA2 | SEMA6 | Breast | ADJ |
SEMA4A | NRP1_PLXNA4 | SEMA4A_NRP1_PLXNA4 | SEMA4 | Breast | DCIS |
SEMA4A | PLXNB2 | SEMA4A_PLXNB2 | SEMA4 | Breast | DCIS |
SEMA4D | PLXNB2 | SEMA4D_PLXNB2 | SEMA4 | Breast | DCIS |
SEMA3C | NRP1_PLXNA4 | SEMA3C_NRP1_PLXNA4 | SEMA3 | Breast | DCIS |
SEMA3D | NRP1_PLXNA4 | SEMA3D_NRP1_PLXNA4 | SEMA3 | Breast | DCIS |
SEMA3C | PLXND1 | SEMA3C_PLXND1 | SEMA3 | Breast | DCIS |
SEMA7A | PLXNC1 | SEMA7A_PLXNC1 | SEMA7 | Breast | DCIS |
SEMA6A | PLXNA4 | SEMA6A_PLXNA4 | SEMA6 | Breast | DCIS |
SEMA3C | NRP1_PLXNA2 | SEMA3C_NRP1_PLXNA2 | SEMA3 | Breast | Healthy |
SEMA3D | NRP1_PLXNA2 | SEMA3D_NRP1_PLXNA2 | SEMA3 | Breast | Healthy |
SEMA3C | NRP2_PLXNA2 | SEMA3C_NRP2_PLXNA2 | SEMA3 | Breast | Healthy |
SEMA3D | NRP2_PLXNA2 | SEMA3D_NRP2_PLXNA2 | SEMA3 | Breast | Healthy |
SEMA3C | PLXND1 | SEMA3C_PLXND1 | SEMA3 | Breast | Healthy |
SEMA4D | PLXNB2 | SEMA4D_PLXNB2 | SEMA4 | Breast | Healthy |
SEMA6A | PLXNA2 | SEMA6A_PLXNA2 | SEMA6 | Breast | Healthy |
SEMA6B | PLXNA2 | SEMA6B_PLXNA2 | SEMA6 | Breast | Healthy |
SEMA4D | PLXNB2 | SEMA4D_PLXNB2 | SEMA4 | Breast | IDC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LXN | SNV | Missense_Mutation | novel | c.326N>C | p.Arg109Thr | p.R109T | Q9BS40 | protein_coding | deleterious(0.01) | benign(0.118) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
LXN | SNV | Missense_Mutation | rs758509037 | c.250N>A | p.Ala84Thr | p.A84T | Q9BS40 | protein_coding | tolerated(0.11) | benign(0.245) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LXN | SNV | Missense_Mutation | c.356N>A | p.Ala119Glu | p.A119E | Q9BS40 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-VS-A9UU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
LXN | SNV | Missense_Mutation | rs758088046 | c.101T>C | p.Val34Ala | p.V34A | Q9BS40 | protein_coding | deleterious(0.01) | benign(0.12) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
LXN | SNV | Missense_Mutation | c.595G>C | p.Val199Leu | p.V199L | Q9BS40 | protein_coding | tolerated(0.08) | benign(0.117) | TCGA-A6-5657-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD | |
LXN | SNV | Missense_Mutation | novel | c.189N>C | p.Gln63His | p.Q63H | Q9BS40 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
LXN | SNV | Missense_Mutation | novel | c.471N>C | p.Trp157Cys | p.W157C | Q9BS40 | protein_coding | tolerated(0.19) | benign(0.068) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LXN | SNV | Missense_Mutation | novel | c.180N>C | p.Glu60Asp | p.E60D | Q9BS40 | protein_coding | tolerated(0.78) | benign(0.026) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LXN | SNV | Missense_Mutation | c.651N>T | p.Lys217Asn | p.K217N | Q9BS40 | protein_coding | deleterious(0) | possibly_damaging(0.604) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LXN | SNV | Missense_Mutation | novel | c.486A>C | p.Lys162Asn | p.K162N | Q9BS40 | protein_coding | deleterious(0.01) | possibly_damaging(0.811) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |